SU2C Lung Cancer Early Detection Challenge Grants
Funding to evaluate liquid-biopsy and other noninvasive platforms (e.g., cfDNA, RNA, urine proteins, breath VOCs) for early-stage lung cancer detection in smokers; Round 1 focuses on sensitivity, selectivity, and cost-effectiveness, with data feeding an integrated Round 2 clinical trial.
Eligibility Criteria:
-
Team must include a Team Leader; optional Co-leader and ≤1 Team Principal (max two institutions). Patient advocate involvement expected; for-profit collaborators allowed.
-
Global eligibility; no citizenship restrictions. FDA-debarred individuals and SU2C SAC members/labs are ineligible.
-
Access to banked samples or budgeted collection required; milestone-driven plans and data sharing for Round 2 are mandatory.
Funding Details:
-
Up to USD 200,000 total for 12–18 months (typical USD 150k–200k). Up to 10% indirect costs.
-
Allowable: regulatory and sample costs, coordinators, database mgmt., limited senior-investigator salary (≤20% of total budget; NIH cap), early-career salaries, research staff, equipment/supplies, travel tied to project/SU2C Summit, publication costs (≤USD 5,000/year).
Deadline:
-
Full application due: October 2, 2025 (11:59 p.m. PDT).
-
Finalist notification: November 3, 2025; virtual selection: November 21, 2025; award notice: December 2025; anticipated start: April 2026.
Where to Go for Further Information:
-
Apply via ProposalCentral; questions: [email protected]. AACR is SU2C’s scientific partner and oversees scientific review.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023